<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487030</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-1643</org_study_id>
    <nct_id>NCT02487030</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to evaluate the efficacy, safety, and tolerability of
      ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV)
      in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2015</start_date>
  <completion_date type="Actual">February 4, 2017</completion_date>
  <primary_completion_date type="Actual">November 11, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4 and 24</time_frame>
    <description>SVR4 and SVR24 were defined as HCV RNA &lt; LLOQ 4 and 24 weeks after the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Virologic Failure</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <description>Virologic failure was defined as
On-treatment virologic failure
confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ, while on treatment (ie, breakthrough),
confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound),
HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse)
Relapse
HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>LDV/SOF 8 wk TN (Cohort 1, Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF for 8 weeks (treatment-naive (TN))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF+RBV for 8 weeks (treatment-naive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF 12 wk TN (Cohort 1, Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF for 12 weeks (treatment-naive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF+RBV for 12 weeks (treatment-naive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF 12 wk TE (Cohort 3, Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF for 12 weeks (treatment-experienced)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF+RBV for 12 weeks (treatment-experienced)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF</intervention_name>
    <description>90/400 mg FDC tablet administered orally once daily</description>
    <arm_group_label>LDV/SOF 8 wk TN (Cohort 1, Group 1)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)</arm_group_label>
    <arm_group_label>LDV/SOF 12 wk TN (Cohort 1, Group 3)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 2)</arm_group_label>
    <arm_group_label>LDV/SOF 12 wk TE (Cohort 3, Group 1)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)</arm_group_label>
    <other_name>Harvoni®</other_name>
    <other_name>GS-5885/GS-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 2)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy

          -  HCV genotype 4 at screening

          -  HCV treatment naive or prior participation in this study or study GS-US-334-0138
             (Cohorts 1 and 2 only)

          -  Cohort 3 only: HCV treatment-experienced (previously received therapy for HCV
             infection with an interferon (IFN)-containing regimen, with or without RBV and/or an
             HCV NS3/NS4A protease inhibitor (PI)

          -  Body mass index (BMI) ≥ 18 kg/m^2

          -  Screening laboratory values within defined thresholds

          -  Use of effective protocol-approved contraception methods

        Key Exclusion Criteria:

          -  History of clinically-significant illness or any other major medical disorder that may
             interfere with treatment, assessment or compliance with the protocol

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Pregnant or nursing females or male with pregnant female partner

          -  Clinically-relevant drug or alcohol abuse within 12 months of screening

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <zip>11559</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mansourah</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibin Al Kawm</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Shiha G, Waked I, Soliman R, Abdelrazek W, Hassany M, Fouad R, et al. Ledipasvir/sofosbuvir for 8 or 12 weeks with or without ribavirin in HCV genotype 4 patients in Egypt. [Abstract OP158]. Asian Pacific Association for the Study of the Liver (APASL); 2017 15-19 February; Shanghai, China</citation>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <results_first_submitted>November 9, 2017</results_first_submitted>
  <results_first_submitted_qc>November 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2017</results_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV genotype 4 (GT-4)</keyword>
  <keyword>HCV</keyword>
  <keyword>Sustained Virologic Response</keyword>
  <keyword>Direct Acting Antiviral</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>GS-7977</keyword>
  <keyword>GS-5885</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>ledipasvir</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in 4 sites in Egypt. The first participant was screened on 07 September 2015 and the last study visit was on 04 February 2017.</recruitment_details>
      <pre_assignment_details>289 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LDV/SOF 8 wk TN (Cohort 1, Group 1)</title>
          <description>Ledipasvir/sofosbuvir (Harvoni®; LDV/SOF) (90/400 mg) fixed dose combination (FDC) tablet administered orally once daily for 8 weeks (wk) in treatment-naive (TN) participants</description>
        </group>
        <group group_id="P2">
          <title>LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + Ribavirin (RBV) tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks in TN participants</description>
        </group>
        <group group_id="P3">
          <title>LDV/SOF 12 wk TN (Cohort 1, Group 3)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 12 weeks in TN participants</description>
        </group>
        <group group_id="P4">
          <title>LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TN participants</description>
        </group>
        <group group_id="P5">
          <title>LDV/SOF 12 wk TE (Cohort 3, Group 1)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily in treatment-experienced (TE) participants</description>
        </group>
        <group group_id="P6">
          <title>LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TE participants</description>
        </group>
        <group group_id="P7">
          <title>LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in SOF or LDV/SOF experienced participants. Participants who completed treatment in Study GS-US-334-0138 with SOF+RBV for 12 or 24 weeks or those who participated in Cohort 1 of this study with LDV/SOF ± RBV for 8 weeks and did not achieve SVR12 were in enrolled into Cohort 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="38"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: participants who were randomized or enrolled and received at least 1 dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>LDV/SOF 8 wk TN (Cohort 1, Group 1)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 8 weeks in TN participants</description>
        </group>
        <group group_id="B2">
          <title>LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks in TN participants</description>
        </group>
        <group group_id="B3">
          <title>LDV/SOF 12 wk TN (Cohort 1, Group 3)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 12 weeks in TN participants</description>
        </group>
        <group group_id="B4">
          <title>LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TN participants</description>
        </group>
        <group group_id="B5">
          <title>LDV/SOF 12 wk TE (Cohort 3, Group 1)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily in TE participants</description>
        </group>
        <group group_id="B6">
          <title>LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TE participants</description>
        </group>
        <group group_id="B7">
          <title>LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in SOF or LDV/SOF experienced participants. Participants who completed treatment in Study GS-US-334-0138 with SOF+RBV for 12 or 24 weeks or those who participated in Cohort 1 of this study with LDV/SOF ± RBV for 8 weeks and did not achieve SVR12 were enrolled into Cohort 2.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="36"/>
            <count group_id="B6" value="38"/>
            <count group_id="B7" value="11"/>
            <count group_id="B8" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="13.9"/>
                    <measurement group_id="B2" value="49" spread="12.2"/>
                    <measurement group_id="B3" value="49" spread="13.0"/>
                    <measurement group_id="B4" value="46" spread="12.1"/>
                    <measurement group_id="B5" value="49" spread="11.8"/>
                    <measurement group_id="B6" value="51" spread="10.1"/>
                    <measurement group_id="B7" value="48" spread="16.3"/>
                    <measurement group_id="B8" value="50.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28b Status</title>
          <description>The CC, CT, and TT alleles are different forms of the IL28b gene.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA</title>
          <units>log10 IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" spread="0.64"/>
                    <measurement group_id="B2" value="5.6" spread="0.63"/>
                    <measurement group_id="B3" value="5.7" spread="0.69"/>
                    <measurement group_id="B4" value="5.8" spread="0.66"/>
                    <measurement group_id="B5" value="5.8" spread="1.10"/>
                    <measurement group_id="B6" value="5.8" spread="1.04"/>
                    <measurement group_id="B7" value="6.2" spread="0.59"/>
                    <measurement group_id="B8" value="5.8" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA Category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</title>
        <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</description>
        <time_frame>Posttreatment Week 12</time_frame>
        <population>Full Analysis Set: all randomized or enrolled participants who had genotype 4 HCV infection and who took at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LDV/SOF 8 wk TN (Cohort 1, Group 1)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 8 weeks in TN participants</description>
          </group>
          <group group_id="O2">
            <title>LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks in TN participants</description>
          </group>
          <group group_id="O3">
            <title>LDV/SOF 12 wk TN (Cohort 1, Group 3)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 12 weeks in TN participants</description>
          </group>
          <group group_id="O4">
            <title>LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TN participants</description>
          </group>
          <group group_id="O5">
            <title>LDV/SOF 12 wk TE (Cohort 3, Group 1)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily in TE participants</description>
          </group>
          <group group_id="O6">
            <title>LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TE participants</description>
          </group>
          <group group_id="O7">
            <title>LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in SOF or LDV/SOF experienced participants. Participants who completed treatment in Study GS-US-334-0138 with SOF+RBV for 12 or 24 weeks or those who participated in Cohort 1 of this study with LDV/SOF ± RBV for 8 weeks and did not achieve SVR12 were enrolled into Cohort 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</title>
          <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</description>
          <population>Full Analysis Set: all randomized or enrolled participants who had genotype 4 HCV infection and who took at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="84.2" upper_limit="99.4"/>
                    <measurement group_id="O2" value="90.5" lower_limit="77.4" upper_limit="97.3"/>
                    <measurement group_id="O3" value="97.7" lower_limit="87.7" upper_limit="99.9"/>
                    <measurement group_id="O4" value="97.6" lower_limit="87.4" upper_limit="99.9"/>
                    <measurement group_id="O5" value="94.4" lower_limit="81.3" upper_limit="99.3"/>
                    <measurement group_id="O6" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)</title>
        <time_frame>12 weeks</time_frame>
        <population>Safety analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LDV/SOF 8 Weeks</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>LDV/SOF + RBV 8 Weeks</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>LDV/SOF 12 Weeks</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>LDV/SOF + RBV 12 Weeks</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)</title>
          <population>Safety analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</title>
        <description>SVR4 and SVR24 were defined as HCV RNA &lt; LLOQ 4 and 24 weeks after the last dose of study drug, respectively.</description>
        <time_frame>Posttreatment Weeks 4 and 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LDV/SOF 8 wk TN (Cohort 1, Group 1)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 8 weeks in TN participants</description>
          </group>
          <group group_id="O2">
            <title>LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks in TN participants</description>
          </group>
          <group group_id="O3">
            <title>LDV/SOF 12 wk TN (Cohort 1, Group 3)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 12 weeks in TN participants</description>
          </group>
          <group group_id="O4">
            <title>LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TN participants</description>
          </group>
          <group group_id="O5">
            <title>LDV/SOF 12 wk TE (Cohort 3, Group 1)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily in TE participants</description>
          </group>
          <group group_id="O6">
            <title>LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TE participants</description>
          </group>
          <group group_id="O7">
            <title>LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in SOF or LDV/SOF experienced participants. Participants who completed treatment in Study GS-US-334-0138 with SOF+RBV for 12 or 24 weeks or those who participated in Cohort 1 of this study with LDV/SOF ± RBV for 8 weeks and did not achieve SVR12 were enrolled into Cohort 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</title>
          <description>SVR4 and SVR24 were defined as HCV RNA &lt; LLOQ 4 and 24 weeks after the last dose of study drug, respectively.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="84.2" upper_limit="99.4"/>
                    <measurement group_id="O2" value="95.2" lower_limit="83.8" upper_limit="99.4"/>
                    <measurement group_id="O3" value="97.7" lower_limit="87.7" upper_limit="99.9"/>
                    <measurement group_id="O4" value="97.6" lower_limit="87.4" upper_limit="99.9"/>
                    <measurement group_id="O5" value="100.0" lower_limit="90.3" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="84.2" upper_limit="99.4"/>
                    <measurement group_id="O2" value="90.5" lower_limit="77.4" upper_limit="97.3"/>
                    <measurement group_id="O3" value="97.7" lower_limit="87.7" upper_limit="99.9"/>
                    <measurement group_id="O4" value="97.6" lower_limit="87.4" upper_limit="99.9"/>
                    <measurement group_id="O5" value="94.4" lower_limit="81.3" upper_limit="99.3"/>
                    <measurement group_id="O6" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Virologic Failure</title>
        <description>Virologic failure was defined as
On-treatment virologic failure
confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ, while on treatment (ie, breakthrough),
confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound),
HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse)
Relapse
HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</description>
        <time_frame>Up to Posttreatment Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LDV/SOF 8 wk TN (Cohort 1, Group 1)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 8 weeks in TN participants</description>
          </group>
          <group group_id="O2">
            <title>LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks in TN participants</description>
          </group>
          <group group_id="O3">
            <title>LDV/SOF 12 wk TN (Cohort 1, Group 3)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 12 weeks in TN participants</description>
          </group>
          <group group_id="O4">
            <title>LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TN participants</description>
          </group>
          <group group_id="O5">
            <title>LDV/SOF 12 wk TE (Cohort 3, Group 1)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily in TE participants</description>
          </group>
          <group group_id="O6">
            <title>LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in TE participants</description>
          </group>
          <group group_id="O7">
            <title>LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)</title>
            <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 12 weeks in SOF or LDV/SOF experienced participants. Participants who completed treatment in Study GS-US-334-0138 with SOF+RBV for 12 or 24 weeks or those who participated in Cohort 1 of this study with LDV/SOF ± RBV for 8 weeks and did not achieve SVR12 were enrolled into Cohort 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Virologic Failure</title>
          <description>Virologic failure was defined as
On-treatment virologic failure
confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ, while on treatment (ie, breakthrough),
confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound),
HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse)
Relapse
HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="2.3"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="2.8"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks + 30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LDV/SOF 8 Weeks</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>LDV/SOF + RBV 8 Weeks</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>LDV/SOF 12 Weeks</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>LDV/SOF + RBV 12 Weeks</title>
          <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily + RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

